Communication Disorders and Artificial Intelligence: A Short Bibliometric Review
Disability CBR & Inclusive Development · 31.12.2025
DOI: 10.20372/dcidj.662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disability CBR & Inclusive Development, erschienen am 31.12.2025. Verfasst von Muskan Chawla und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Aim - Due to the quadrupling in publications since 2022, a bibliometric study is a need of an hour. This study offers a thorough analysis of communication disorders across an appropriate time period. Methodology - Based on the Pubmed database, a total of 8713 papers about communication disorders were examined during the time period 1963-2022. At the end, 6233 publications and 7012 key terms were retained specially related to communication disorders. Result - This study systematically reviews research articles on numerous parameters such as (i) cumulative frequency of keywords (ii) analysis of common key terms, (iii) top 10 research scientists, (iv) research article production of top 10 researchers, (v) co-occurrence of key terms Conclusion - The paper examines the literature using meta-perspectives to analyses the quantitative traits of communication disorders. The proposed analytical study will be a vital resource for substantive discussion about potential future research plans.
Schlagwörter
Zitieren
APA
Chawla, M., Panda, S. N., & KHULLAR, V. (2025). Communication Disorders and Artificial Intelligence: A Short Bibliometric Review. Disability CBR & Inclusive Development. https://doi.org/10.20372/dcidj.662
Vancouver
Chawla M, Panda SN, KHULLAR V. Communication Disorders and Artificial Intelligence: A Short Bibliometric Review. Disability CBR & Inclusive Development. 2025. doi:10.20372/dcidj.662
BibTeX
@article{Chawla2025,
author = {Chawla, Muskan and Panda, Surya Narayan and KHULLAR, VIKAS},
title = {Communication Disorders and Artificial Intelligence: A Short Bibliometric Review},
journal = {Disability CBR & Inclusive Development},
year = {2025},
doi = {10.20372/dcidj.662}
}
EUVIMED